Where does Acadia Pharmaceuticals's cash flow data come from?

Every line is extracted from Acadia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	$391M+72.7%	$226.45M+469%	-$61.29M+71.6%	-$215.98M-28.7%
Depreciation and amortization	$871K-5.3%	$920K-36.9%	$1.46M-28.0%	$2.03M-9.4%
Stock-based compensation	$52.14M-22.2%	$67.05M+0.9%	$66.42M-2.6%	$68.2M+7.2%
Deferred income taxes	——	$0—	$0—	——
Change in accounts receivable	$22.72M+4,713%	$472K-98.7%	$36.07M—	——
Change in inventories	$19.45M-60.8%	$49.55M+72.0%	$28.81M+1,293%	-$2.42M-155%
Change in accounts payable	-$5.29M-291%	-$1.35M-128%	$4.8M—	——
Change in accrued liabilities	-$19.27M-127%	$71.06M-23.7%	$93.17M—	——
Change in other assets	$3.85M-76.8%	$16.59M—	——	——
Change in other liabilities	$1.08M-62.8%	$2.91M-52.1%	$6.07M—	——
Change in prepaid expenses	——	——	——	——
Amortization of intangible assets	$10.89M-27.2%	$14.96M+266%	$4.09M—	$0-100%
Change in receivables	$20.82M—	——	——	——
Net cash from operating activities	——	$157.72M+844%	$16.7M+115%	-$114.04M+9.3%
Capital expenditures	$4.69M—	——	$50K—	$0-100%
Purchases of investments	$692.57M+37.1%	$505.1M+36.5%	$369.99M+1.9%	$363.17M-26.3%
Proceeds from maturities/sales of investments	$493.53M+50.2%	$328.57M-23.6%	$429.78M-1.5%	$436.42M+3.2%
Purchases of intangible assets	——	$0-100%	$40M—	——
Net cash from investing activities	-$302.56M—	——	$32.35M—	——
Proceeds from issuance of common stock	$49.88M+629%	$6.85M-72.8%	$25.13M+206%	$8.2M-54.9%
Net cash from financing activities	$49.88M+629%	$6.85M-72.8%	$25.13M+206%	$8.2M-54.9%
Effect of exchange rate changes on cash	$26K+128%	-$94K-422%	-$18K—	——
Net increase (decrease) in cash	——	$133.93M+81.5%	$73.81M+326%	-$32.59M—
Income taxes paid	$25.17M+28.9%	$19.52M+234%	$5.85M+167%	$2.19M+111%
Accretion (Amortization) of Discounts and Premiums, Investments	$5.42M-41.7%	$9.3M+23.5%	$7.53M+175%	$2.74M+214%
Amortization of capitalized software and acquired intangible assets	$10.89M-27.2%	$14.96M+266%	$4.09M—	$0-100%
Depreciation	$871K-5.3%	$920K-36.9%	$1.46M-28.0%	$2.03M-9.4%
Gain (Loss) on Disposition of Other Assets	$0-100%	$146.52M—	$0—	$0—
Increase (Decrease) in Accounts Receivable and Other Operating Assets	$20.82M—	——	——	——
Increase Decrease In Operating Lease Assets	-$8.67M-15.5%	-$7.5M-30.0%	-$5.77M+12.1%	-$6.57M-4.4%
Increase Decrease In Operating Lease Liabilities	-$6.52M+16.4%	-$7.79M-32.7%	-$5.87M+25.8%	-$7.92M-45.7%
Increase (Decrease) in Other Operating Assets	$2.86M+2,541%	-$117K—	——	——
Increase (Decrease) in Prepaid Expense	——	——	——	——
Payments to Acquire Intangible Assets	——	$0-100%	$40M—	——
Proceeds From Sale And Maturity Of Available For Sale Securities	$493.53M+50.2%	$328.57M-23.6%	$429.78M-1.5%	$436.42M+3.2%
Accrued Inventory Purchases	——	——	$0—	$0—
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	$26K+128%	-$94K-422%	-$18K—	——
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1	$0—	——	——	$0—
Property And Equipment Purchases In Accrued Liabilities	——	——	——	——
Stock Based Compensation Capitalized	——	$425K+438%	$79K—	——
Income Taxes Paid, Net	$25.17M+28.9%	$19.52M+234%	$5.85M+167%	$2.19M+111%
Free cash flow	——	——	——	-$114.04M+10.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Acadia Pharmaceuticals's cash flow data come from?: Every line is extracted from Acadia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.